Collectively, the current study defined MAGI2-AS3 as a novel tumor suppressor in prostate cancer and suggested MAGI2-AS3 as a biomarker and drug target for the patients with prostate cancer. The gene discussed is MAGI2; the disease is prostate carcinoma.